纤维化连续指数(CIF):改进MPN患者的评估与分类
研究开发了基于骨髓穿刺活检样本(n=107)的机器学习方法——纤维化连续指数(CIF),用于定量网织纤维化。CIF联合巨核细胞特征分析可高精度区分原发性血小板增多症(ET)与纤维化前骨髓纤维化(AUC=0.94),并在35例ET患者中识别出预测ET后骨髓纤维化的特征(AUC=0.77)。
要点
- CIF可增强骨髓活检中纤维化的检测与监测,并辅助MPN亚型分类。
- CIF联合巨核细胞特征分析区分ET与纤维化前骨髓纤维化,AUC=0.94。
- 35例ET患者样本分析中,CIF特征可预测ET后骨髓纤维化,AUC=0.77。
核心结论
- CIF可增强骨髓活检中纤维化的检测与监测,并辅助MPN亚型分类。
- CIF联合巨核细胞特征分析可高精度区分ET与纤维化前骨髓纤维化(AUC=0.94)。
- CIF在识别有疾病进展风险的MPN患者方面显示出前景,35例ET患者中识别出预测ET后骨髓纤维化的特征(AUC=0.77)。
- 纤维化自动分析有潜力进一步细化疾病分类边界,并为未来微环境因素研究提供信息。
研究设计与样本
- 研究采用机器学习方法,使用诊断为MPN或反应性骨髓的患者骨髓穿刺活检样本(n=107)开发纤维化连续指数(CIF)。
- 在35例诊断为ET并纳入Primary Thrombocythemia-1试验的患者样本中分析预测ET后骨髓纤维化的特征。
主要发现
- CIF增强了骨髓活检中纤维化的检测与监测,并辅助MPN亚型分类。
- CIF联合巨核细胞特征分析区分ET与纤维化前骨髓纤维化,AUC=0.94。
- 35例ET患者样本分析中,CIF识别出预测ET后骨髓纤维化的特征,AUC=0.77。
关键数值与推荐
- 区分ET与纤维化前骨髓纤维化的AUC=0.94。
- 预测ET后骨髓纤维化的AUC=0.77(35例ET患者)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The grading of fibrosis in myeloproliferative neoplasms (MPN) is an important component of disease classification, prognostication and monitoring. However, current fibrosis grading systems are only semi-quantitative and fail to fully capture sample heterogeneity. To improve the quantitation of reticulin fibrosis, we developed a machine learning approach using bone marrow trephine (BMT) samples (n = 107) from patients diagnosed with MPN or a reactive marrow. The resulting Continuous Indexing of Fibrosis (CIF) enhances the detection and monitoring of fibrosis within BMTs, and aids MPN subtyping. When combined with megakaryocyte feature analysis, CIF discriminates between the frequently challenging differential diagnosis of essential thrombocythemia (ET) and pre-fibrotic myelofibrosis with high predictive accuracy [area under the curve = 0.94]. CIF also shows promise in the identification of MPN patients at risk of disease progression; analysis of samples from 35 patients diagnosed with ET and enrolled in the Primary Thrombocythemia-1 trial identified features predictive of post-ET myelofibrosis (area under the curve = 0.77). In addition to these clinical applications, automated analysis of fibrosis has clear potential to further refine disease classification boundaries and inform future studies of the micro-environmental factors driving disease initiation and progression in MPN and other stem cell disorders.
引用
- Ryou H, Sirinukunwattana K, Aberdeen A, et al. Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients. Leukemia. 2022. PMID: 36470992. doi:10.1038/s41375-022-01773-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。